What is SABS (SABS) stock price today?

SABS (SABS) is currently trading at $3.44, down 1.99% today.

What is SABS P/E ratio?

SABS's P/E ratio is -5.20. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SABS return on equity (ROE)?

SABS's return on equity (ROE) is 8.61%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is SABS's market cap?

SABS has a market capitalization of $32.88M.

NASDAQ · Biotechnology

SABS (SABS) Stock

$3.44 -1.99% NASDAQ: SABS Healthcare

Valuation

Metric	Value
Price	$3.44
Market Cap	$32.88M
P/E Ratio	-5.20
P/B Ratio	0.26
P/S Ratio	0.00
EPS (TTM)	$-0.79
52-Week High	$6.60
52-Week Low	$1.67
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	8.61%
ROA	7.51%
ROCE	-32.24%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.03
Current Ratio	9.18

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$61.0M	$24.0M	$2.0M	$1.0M	$0
Operating Profit	$-13.0M	$-29.0M	$-38.0M	$-43.0M	$-49.0M
Net Profit	$-17.0M	$-19.0M	$-42.0M	$-34.0M	$13.0M
EPS	$-6.30	$-4.31	$-7.64	$-3.68	$-0.79
Op Margin	-22.0%	-121.0%	-1700.5%	-3244.9%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$81.0M	$51.0M	$84.0M	$44.0M	$173.0M
Total Liabilities	$43.0M	$20.0M	$27.0M	$18.0M	$21.0M
Cash	$33.0M	$15.0M	$57.0M	$9.0M	$11.0M
Borrowings	$9.0M	$6.0M	$6.0M	$5.0M	$6.0M

Latest News

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment Insider Monkey · Jul 15, 2026 Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes GlobeNewswire · Jul 7, 2026 Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? Insider Monkey · Jul 5, 2026 Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) Insider Monkey · Jun 30, 2026 Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target MT Newswires · Jun 24, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$2.0M	$-23.0M	$-25.0M	$-34.0M	$-45.0M
Investing Cash Flow	$-22.0M	$-4.0M	$0	$-12.0M	$-123.0M
Financing Cash Flow	$34.0M	$-5.0M	$60.0M	$0	$0
Net Cash Flow	$27.0M	$-24.0M	$42.0M	$-48.0M	$2.0M
Free Cash Flow	$-9.0M	$-26.0M	$-25.0M	$-35.0M	$-46.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-156.25%
Quick Ratio	11.45
Interest Coverage	—
Return 1Y	42.52%
Return 3Y	-58.25%
Return 5Y	-96.35%

Ownership

Insiders Held0.84%

Institutions Held92.44%

Institutions Float Held93.22%

Institutional Holder	Shares	Report Date
Vivo Capital, LLC	11,420,000	2026-03-31
Caligan Partners, LP	7,967,207	2026-03-31
Perceptive Advisors Llc	6,431,743	2026-03-31
Commodore Capital Lp	4,401,500	2026-03-31
RA Capital Management, L.P.	4,401,500	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANTX	$4.93	+0.20%	-4.76	$177.56M	0.00%
BOLD	$2.48	-3.50%	-0.56	$55.74M	0.00%
EVAXEvaxion Biotech A/S	$3.05	+0.66%	-1.99	$19.27M	0.00%
GBIOGeneration Bio Co.	$5.34	+0.00%	-0.87	$35.98M	0.00%
ITRMIterum Therapeutics plc	$0.03	-10.98%	-0.06	$1.60M	0.00%

About SABS

SABS is led by CEO Samuel J. Reich, employs 63 people, headquartered in US, publicly traded since 2021.

SABS stock trades at $3.44 with a market capitalization of $32.88M. The stock is valued at a price-to-earnings (P/E) ratio of -5.20, price-to-book of 0.26, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.67 and $6.60, and currently trades 47.9% below its 52-week high.

On profitability, SABS generates a return on equity (ROE) of 8.61%, return on capital employed of -32.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides